1
Zhi Hong, Jean Luc Girardet, Kanda Ramasamy, Johnson Lau: Nucleoside compounds and uses thereof. Ribapharm, Brown Raysman Millstein Felder & Steiner, November 9, 2004: US06815542 (68 worldwide citation)

Nucleosides, novel nucleoside analog compounds and their novel prodrug forms are disclosed. The novel compounds, prodrugs, or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neo ...


2

3
Robert Tam, Devron Averett, Guangyi Wang, Kanda Ramasamy: L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine. Robert D Fish, Fish & Associates, September 24, 2002: US06455690 (35 worldwide citation)

Novel nucleosides having the structure of Formula 1 and Formula 2 are contemplated. In one aspect of the invention, controlled release dosage forms are particularly contemplated. Further, alternative routes of administration of the nucleosides having the structure of Formula 1 or Formula 2 are conte ...


4
Kanda Ramasamy, Robert Tam: Tirazole nucleoside analogs and methods for using same. Valeant Pharmaceuticals International, Brown Raysman Millstein Felder & Steiner, June 6, 2006: US07056895 (16 worldwide citation)

Novel heterocyclic aromatic compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compoun ...


5
Haoyun An, Kanda Ramasamy, Stephanie Shaw: -modified nucleosides, Synthesis and use of 2′-substituted-N. Valeant Pharmaceuticals North America, McDermott Will & Emery, September 21, 2010: US07799908 (1 worldwide citation)

An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is ...


6
Haoyun An, Kanda Ramasamy, Stephanie Shaw: Synthesis and use of 2′-substituted-N6-modified nucleosides. Valeant Pharmaceuticals North America, Len S Smith, Judith U Kim, Matthew S Bodenstein, November 5, 2013: US08575331

An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is ...


7
Kanda Ramasamy, Jean Luc Girardet, Haoyun An, Zhi Hong, Robert Orr: Synthesis for hydroxyalkylated heterocyclic bases. Valeant Research & Development, Saliwanchik Lloyd & Saliwanchik, May 13, 2008: US07371857

A hydroxyalkylated heterocyclic base is prepared by reacting a heterocyclic base with an alkylene carbonate in dimethylacetamide as a solvent, wherein the hydroxyalkylated heterocyclic base is isolated from the solvent using isopropanol or tert-butylmethylether.


8
Zhi Hong, Jean Luc Girardet, Kanda Ramasamy, Johnson Lau: Nucleoside compounds and uses thereof. Robert D Fish Rutan & Tucker, January 1, 2004: US20040002596-A1

Nucleosides, novel nucleoside analog compounds and their novel prodrug forms are disclosed. The novel compounds, prodrugs, or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neo ...


9
Kanda Ramasamy, Robert Tam, Devron Averett: Monocyclic L-nucleosides, analogs and uses thereof. Rutan & Tucker, January 23, 2003: US20030018186-A1

Novel monocyclic L-Nucleoside compounds have the general formula 1 Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compou ...


10
Kanda Ramasamy, Robert Tam: Heterocyclic aromatic compounds and uses thereof. Rutan & Tucker, October 24, 2002: US20020156030-A1

Novel heterocyclic aromatic compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compoun ...